This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, J. Articles by Schaison, G. Search for Related Content PubMed PubMed Citation Articles by Young, J. Articles by Schaison, G.

Antimüllerian Hormone in Patients with Hypogonadotropic Hypogonadism

Service d’Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre (J.Y., B.C., P.C., G.S.), 94270 Kremlin Bicêtre and Unité de Recherches sur l’Endocrinologie du Développement (INSERM U 493), Ecole Normale Supérieure (R.R., N.J.) 92120 Montrouge, France

Address all correspondence and request for reprints to: Gilbert Schaison, M.D., Service d’Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre 94270 Kremlin Bicêtre, France.

Antimüllerian hormone (AMH) is produced by immature Sertoli cells until pubertal maturation. At puberty, elevation of serum testosterone correlates with a decrease in serum AMH. To further investigate the hormonal control of AMH secretion, serum AMH levels were measured in 20 normal men (20–60 yr), in 12 patients (19–30 yr) with congenital hypogonadotropic hypogonadism (CHH), and in 18 patients (19–65 yr) with acquired hypogonadotropic hypogonadism (AHH) either untreated or during testosterone or human chorionic gonadotropin (hCG) therapy. Mean serum AMH levels in normal adult men were low (20 ± 4.9 pmol/L). In untreated CHH patients, mean serum AMH levels were significantly higher than in normal men (292 ± 86 pmol/L, P < 0.001) and were similar to those previously reported in prepubertal boys. In men with AHH, mean serum AMH levels were also significantly increased (107 ± 50 pmol/L; P < 0.01) when compared with healthy men but were less than in men with CHH. In addition, in 10 patients treated for prostate cancer, a modest but significant increase of serum AMH (from 11.4 ± 5.7 pmol/L to 49 ± 9.9 pmol/L; P < 0.01) was observed 12 months after suppression of the gonadal axis with the GnRH agonist Triptorelin (3.75 mg IM once a month).

Plasma testosterone (T) and serum AMH levels were measured at baseline and at 3 and 6 months in 10 HH patients (6 CHH and 4 AHH) treated with hCG (1500 IU/twice weekly for 6 months) and in 8 HH (4 CHH and 4 AHH) patients treated with T (T enanthate 250 mg/3 weeks for 6 months). hCG treatment induced an increase of plasma T (from 1.0 ± 0.7 to 11 ± 2.4 and 19 ± 4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314 ± 93 to 56 ± 30 and 17 ± 4.3 pmol/L). The similar increase in plasma T levels (from 1.4 ± 1.0 to 15.6 ± 4.2 and 23 ± 6.2 ng/mL) obtained with exogenous T induced a lesser decrease of serum AMH (from 221 ± 107 pmol/L to 114 ± 50 and 66 ± 17 pmol/L, at 3 and 6 months respectively).

In conclusion, high plasma AMH levels in CHH patients are related to the absence of pubertal maturation of Sertoli cells. The high AMH levels in AHH and its increase after Triptorelin-induced gonadotropin deficiency suggest that the suppression of AMH is a reversible phenomenon. Finally, the inhibition of AMH production by Sertoli cells is induced by intratesticular T.

This article has been cited by other articles:

				G. F. Kerkhof, R. W. J. Leunissen, R. H. Willemsen, F. H. de Jong, T. Stijnen, and A. C. S. Hokken-Koelega Influence of Preterm Birth and Birth Size on Gonadal Function in Young Men J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4243 - 4250. [Abstract] [Full Text] [PDF]

				H. J. Hirsch, T. Eldar-Geva, F. Benarroch, O. Rubinstein, and V. Gross-Tsur Primary Testicular Dysfunction Is a Major Contributor to Abnormal Pubertal Development in Males with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2262 - 2268. [Abstract] [Full Text] [PDF]

				K. Boukari, G. Meduri, S. Brailly-Tabard, J. Guibourdenche, M. L. Ciampi, N. Massin, L. Martinerie, J.-Y. Picard, R. Rey, M. Lombes, et al. Lack of Androgen Receptor Expression in Sertoli Cells Accounts for the Absence of Anti-Mullerian Hormone Repression during Early Human Testis Development J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1818 - 1825. [Abstract] [Full Text] [PDF]

				A.A. Sinisi, D. Esposito, L. Maione, M.C. Quinto, D. Visconti, A. De Bellis, A. Bellastella, G. Conzo, and G. Bellastella Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism Hum. Reprod., May 1, 2008; 23(5): 1029 - 1034. [Abstract] [Full Text] [PDF]

				T. Piltonen, L. Morin-Papunen, R. Koivunen, A. Perheentupa, A. Ruokonen, and J. S. Tapanainen Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome Hum. Reprod., July 1, 2005; 20(7): 1820 - 1826. [Abstract] [Full Text] [PDF]

				J. Young, P. Chanson, S. Salenave, M. Noel, S. Brailly, M. O'Flaherty, G. Schaison, and R. Rey Testicular Anti-Mullerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 724 - 728. [Abstract] [Full Text] [PDF]

				C. Lukas-Croisier, C. Lasala, J. Nicaud, P. Bedecarras, T. R. Kumar, M. Dutertre, M. M. Matzuk, J.-Y. Picard, N. Josso, and R. Rey Follicle-Stimulating Hormone Increases Testicular Anti-Mullerian Hormone (AMH) Production through Sertoli Cell Proliferation and a Nonclassical Cyclic Adenosine 5'-Monophosphate-Mediated Activation of the AMH Gene Mol. Endocrinol., April 1, 2003; 17(4): 550 - 561. [Abstract] [Full Text] [PDF]

				N. Pitteloud, F. J. Hayes, P. A. Boepple, S. DeCruz, S. B. Seminara, D. T. MacLaughlin, and W. F. Crowley Jr. The Role of Prior Pubertal Development, Biochemical Markers of Testicular Maturation, and Genetics in Elucidating the Phenotypic Heterogeneity of Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 152 - 160. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]